PROCEPT BioRobotics

PROCEPT BioRobotics develops surgical robotic systems for urology. Its AquaBeam platform delivers Aquablation therapy, an image-guided, robotic-assisted waterjet procedure for treating benign prostatic hyperplasia in hospital and surgical settings.

Facts

Segment: Surgical
Country: United States
Ticker: PRCT
Website: https://www.procept-biorobotics.com/

Market context

PROCEPT is a listed surgical robotics pure play with commercial systems in urology, where robotic imaging and waterjet control define the clinical workflow.

Vicarious Surgical - comparable profile - peer: Surgical Robotics Companies
True Health Medical-B / 真健康医疗-B - comparable profile - peer: Surgical Robotics Companies
Moon Surgical - comparable profile - peer: Surgical Robotics Companies

View market context

Financials

PRCT - NASDAQ - USD

View financials

Funding

2018-02-21 - Equity financing - $118M - PROCEPT BioRobotics raises $118 million equity financing - PROCEPT BioRobotics raised $118 million in equity financing to support worldwide commercialisation of Aquablation therapy and the AquaBeam surgical robotics system. - source: ir.procept-biorobotics.com

View funding

Investors

CPMG - Participant - Unknown - 1 funding event - first seen 2018-02-21
Perceptive Advisors - Participant - Angel / Individual - 1 funding event - first seen 2018-02-21
Viking Global Investors - Lead - VC - 1 funding event - first seen 2018-02-21

View investors

Timeline

2024-08-20 - Regulatory - PROCEPT BioRobotics receives FDA clearance for HYDROS robotic system - PROCEPT BioRobotics received FDA 510(k) clearance for HYDROS, its next-generation robotic system for Aquablation therapy. HYDROS extends the company''s urology robotics platform with image-guided planning and treatment workflow updates. The regulatory… - source: ir.procept-biorobotics.com
2021-09-15 - Market Signal - PROCEPT BioRobotics prices Nasdaq IPO - PROCEPT expected its common stock to begin trading on the Nasdaq Global Market on September 15, 2021. The IPO was priced at $25.00 per share. The company offered all shares in the upsized offering. - source: ir.procept-biorobotics.com

View timeline

Team

Larry L. Wood - President and Chief Executive Officer - This role identifies Larry L. Wood as part of PROCEPT BioRobotics's leadership or founding team.
Kevin Waters - Executive Vice President and Chief Financial Officer

View team